Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 2
R&D Momentum
35/100
Pipeline Velocity
15/100
Trial Completion Rate
75/100
Pipeline Concentration
56/100
Pipeline Freshness
83/100
Strategic Signals
Activity
Last 14 days
A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Nuplazid — NUPLAZID
Application NDA210793 (NDA)
Nuplazid — NUPLAZID
Application NDA207318 (NDA)
Daybue Stix — DAYBUE
Application NDA217026 (NDA)
Daybue Stix — DAYBUE STIX
Application NDA219884 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)